Pluristem

Yaky Yanay, CEO of Pluristem, speaks at the Global Investment Forum

Pluristem CEO touts a new generation of medical treatments

Yaky Yanay at Dubai conference: They put Israel on the map as an island of innovation

By LIOR NOVIK
03/06/2021

Pluristem’s placenta cells induce body to create new blood cells - study

Pluristem's PLX-R18 aims to stimulate the regenerative potential of the bone marrow to enhance the production of all three blood cell lineages: hemoglobin, neutrophil and platelet counts.

bioreactor pluristem

Pluristem names members of coronavirus Steering Committee

The committee is composed of five prominent infectious diseases, critical care, internal medicine and pumonology specialists from around the world

THE SOURASKY Medical Center in Tel Aviv.

Pluristem to enroll participants for GvHD treatment at Sourasky

"We have so far found no negative side effects from the use of the PLX-PAD cells in the treatment of steroid-refractory cGvHD."

Photos showing Pluristem CEO and COO Yaky Yanai, and Pluristem trials

Israeli and Emirati companies join forces to develop COVID-19 treatment

The Israeli-Emirati joint projects aim to utilize each company's strengths in order to achieve results that will integrate the expertise of both companies.

FDA clears Haifa-based Pluristem’s COVID-19 Expanded Access Program

More coronavirus patients who do not qualify for the company’s clinical trial will now be able to receive treatment

Pluristem joins CRISPR-IL to develop next-gen genome editing products

“We see cell therapy and gene editing as highly synergistic methods to treat and cure diseases using advanced technologies."

Israel’s Pluristem: 75% of treated COVID-19 patients off ventilators

The survival rate is 87.5%, Pluristem Therapeutics reported.

bioreactor pluristem

Israel's Pluristem FDA approved for study in treatment of severe COVID-19

Six critically ill coronavirus patients in Israel who were considered high-risk for mortality were treated with Pluristem and survived.

Israel's Pluristem secures €50m. EU financing to boost COVID-19 treatment

The financing is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the financial pillar of the European Union's Investment Plan for Europe.

25/04/2020
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy